☰

Noel P. Bouck - Publications

Affiliations: 
Northwestern University, Evanston, IL 
Area:
Cell Biology
Tree Info Grants Similar researchers PubMed Report error

43 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2004 Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV. Alpha1-antitrypsin inhibits angiogenesis and tumor growth. International Journal of Cancer. 112: 1042-8. PMID 15316942 DOI: 10.1002/Ijc.20494  0.413
2004 Boehm BO, Lang G, Feldmann B, Kurkhaus A, Rosinger S, Volpert O, Lang GK, Bouck N. Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor. a pilot study. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 35: 382-6. PMID 12920663 DOI: 10.1055/S-2003-41362  0.364
2003 Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nature Medicine. 9: 774-80. PMID 12740569 DOI: 10.1038/Nm870  0.403
2003 Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia. 46: 394-400. PMID 12687338 DOI: 10.1007/S00125-003-1040-9  0.319
2002 Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. American Journal of Ophthalmology. 134: 220-7. PMID 12140029 DOI: 10.1016/S0002-9394(02)01549-0  0.436
2002 Bouck N. PEDF: anti-angiogenic guardian of ocular function Trends in Molecular Medicine. 8: 330-334. PMID 12114112 DOI: 10.1016/S1471-4914(02)02362-6  0.516
2002 Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nature Medicine. 8: 349-57. PMID 11927940 DOI: 10.1038/Nm0402-349  0.489
2002 Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. International Journal of Cancer. 98: 682-9. PMID 11920636 DOI: 10.1002/Ijc.10247  0.435
2001 Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. The Prostate. 49: 293-305. PMID 11746276 DOI: 10.1002/Pros.10025  0.412
2001 Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. The American Journal of Pathology. 159: 1949-56. PMID 11696456 DOI: 10.1016/S0002-9440(10)63042-8  0.328
2001 Jiménez B, Volpert OV, Reiher F, Chang L, Muñoz A, Karin M, Bouck N. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene. 20: 3443-8. PMID 11423995 DOI: 10.1038/Sj.Onc.1204464  0.379
2001 Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes & Development. 15: 1373-82. PMID 11390357 DOI: 10.1101/Gad.193501  0.359
2001 Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor Proceedings of the National Academy of Sciences of the United States of America. 98: 2593-2597. PMID 11226284 DOI: 10.1073/Pnas.031252398  0.529
2001 Reiher FK, Anovich M, Huang H, Smith ND, Bouck NP, Campbell SC. The ROLE OF HYPOXIA AND P53 IN THE REGULATION OF ANGIOGENESIS IN BLADDER CANCER The Journal of Urology. 165: 2075-2081. DOI: 10.1016/S0022-5347(05)66297-0  0.42
2000 Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Lüttges J, Klöppel G, Graeven U, Eilert-Micus C, Hintelmann A, Schmiegel W. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis Proceedings of the National Academy of Sciences of the United States of America. 97: 9624-9629. PMID 10944227 DOI: 10.1073/Pnas.97.17.9624  0.416
2000 Gradishar WJ, Soff G, Liu J, Cisneros A, French S, Rademaker A, Benson AB, Bouck N. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Oncology. 58: 324-33. PMID 10838499 DOI: 10.1159/000012120  0.322
2000 Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nature Medicine. 6: 196-9. PMID 10655109 DOI: 10.1038/72303  0.454
2000 Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 Nature Medicine. 6: 41-48. PMID 10613822 DOI: 10.1038/71517  0.461
2000 Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Luettges J, Kloeppel G, Graeven U, Eilert-Micus C, Hintelmann A, Schmiegel W. DPC4/Smad4 mediated tumor suppression in pancreatic cancer cells through suppression of angiogenesis Gastroenterology. 118: A50. DOI: 10.1016/S0016-5085(00)82271-4  0.359
1999 Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (New York, N.Y.). 285: 245-8. PMID 10398599 DOI: 10.1126/Science.285.5425.245  0.507
1999 Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Molecular Pharmacology. 55: 332-8. PMID 9927626 DOI: 10.1124/Mol.55.2.332  0.307
1998 Vogler WR, Liu J, Volpert O, Ades EW, Bouck N. The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo. Cancer Investigation. 16: 549-53. PMID 9844614 DOI: 10.3109/07357909809032884  0.474
1998 Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP. Inhibition of angiogenesis by interleukin 4. The Journal of Experimental Medicine. 188: 1039-46. PMID 9743522 DOI: 10.1084/Jem.188.6.1039  0.34
1998 Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proceedings of the National Academy of Sciences of the United States of America. 95: 6343-8. PMID 9600967 DOI: 10.1073/Pnas.95.11.6343  0.359
1998 Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS. Multiple Forms of Angiostatin Induce Apoptosis in Endothelial Cells Blood. 92: 4730-4741. DOI: 10.1182/Blood.V92.12.4730.424K20_4730_4741  0.422
1997 Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proceedings of the National Academy of Sciences of the United States of America. 94: 10868-72. PMID 9380726 DOI: 10.1073/Pnas.94.20.10868  0.411
1997 Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. The Journal of Cell Biology. 138: 707-17. PMID 9245797 DOI: 10.1083/Jcb.138.3.707  0.354
1997 Tolsma SS, Stack MS, Bouck N. Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. Microvascular Research. 54: 13-26. PMID 9245640 DOI: 10.1006/Mvre.1997.2015  0.467
1997 Volpert OV, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 14: 1495-502. PMID 9136993 DOI: 10.1038/Sj.Onc.1200977  0.495
1997 Lingen MW, DiPietro LA, Solt DB, Bouck NP, Polverini PJ. The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation. Carcinogenesis. 18: 329-38. PMID 9054625 DOI: 10.1093/Carcin/18.2.329  0.343
1996 Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic Advances in Cancer Research. 69: 135-174. PMID 8791681 DOI: 10.1016/S0065-230X(08)60862-3  0.433
1996 Volpert O, Jackson D, Bouck N, Linzer DI. The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology. 137: 3871-6. PMID 8756559 DOI: 10.1210/Endo.137.9.8756559  0.34
1996 Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats Journal of Clinical Investigation. 98: 671-679. PMID 8698858 DOI: 10.1172/Jci118838  0.482
1996 Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Research and Treatment. 36: 119-26. PMID 8534861 DOI: 10.1007/Bf00666034  0.461
1995 Jackson D, Volpert OV, Bouck N, Linzer DI. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science (New York, N.Y.). 266: 1581-4. PMID 7527157 DOI: 10.1126/Science.7527157  0.413
1994 Dameron KM, Volpert OV, Tainsky MA, Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin Cold Spring Harbor Symposia On Quantitative Biology. 59: 483-489. PMID 7587102 DOI: 10.1101/Sqb.1994.059.01.053  0.329
1994 Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 Science. 265: 1582-1584. PMID 7521539 DOI: 10.1126/Science.7521539  0.399
1994 Johnson MD, Kim HC, Chesler L, Tsao‐Wu G, Polverini PJ, Bouck N. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. Journal of Cellular Physiology. 160: 194-202. PMID 7517405 DOI: 10.1002/Jcp.1041600122  0.487
1993 Koch AE, Friedman J, Burrows JC, Haines GK, Bouck NP. Localization of the Angiogenesis Inhibitor Thrombospondin in Human Synovial Tissues Pathobiology. 61: 1-6. PMID 8216817 DOI: 10.1159/000163752  0.364
1993 Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. The Journal of Cell Biology. 122: 497-511. PMID 7686555 DOI: 10.1083/Jcb.122.2.497  0.409
1991 Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods in Enzymology. 198: 440-50. PMID 1857235 DOI: 10.1016/0076-6879(91)98044-7  0.394
1990 Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proceedings of the National Academy of Sciences of the United States of America. 87: 6624-8. PMID 1697685 DOI: 10.1073/Pnas.87.17.6624  0.438
1989 Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell. 56: 345-55. PMID 2464438 DOI: 10.1016/0092-8674(89)90238-9  0.422
Show low-probability matches.